RE:RE:RE:EU approves first I/O combination" Major catalysts are approaching in this field [of anti-PD-(L)1 drugs]– for Merck and other big pharma developers of anti-PD-(L)1 drugs alike. The most immediate is a 15 September US FDA action date to decide on the approvability of a SC formulation of Roche’s Tecentriq, on the basis of the phase 3 Imscin-01 trial that the Swiss group quietly toplined as positive a year ago."
https://www.oncologypipeline.com/apexonco/subcutaneous-answer-pd-1s-patent-problem